Litigation Details for Purdue Pharma LP v. Collegium Pharmaceutical Inc. (D. Del. 2015)

« Back to Dashboard

Purdue Pharma LP v. Collegium Pharmaceutical Inc. (D. Del. 2015)

Docket	1:15-cv-00260	Date Filed	2015-03-24
Court	District Court, D. Delaware	Date Terminated	2015-10-22
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	7,674,799; 7,674,800; 7,683,072
Link to Docket	External link to docket

Details for Purdue Pharma LP v. Collegium Pharmaceutical Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-24				External link to document
2015-03-24	29		quot;): U.S. Patent Nos. 7,674,799, 7,674,800, and 7,683,072 (''the listed patents"). Additionally… opioid formulation, U.S. Patent No. 8,652,497 ("the '497 patent"), which is not listed…involve the '497 patent asserted in the instant litigation. The listed patents are directed to and…APl 12 that is the subject of numerous patents ('497 patent, col. 1:42-46) and is commercially available…(collectively, "Purdue"), filed this patent infringement action against Collegium Pharmaceutical	External link to document
2015-03-24	31		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,674,799; 7,674,800; 7,683,072…2015 22 October 2015 1:15-cv-00260 830 Patent None District Court, D. Delaware	External link to document
2015-03-24	39		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,674,799; 7,674,800; 7,683,072…2015 22 October 2015 1:15-cv-00260 830 Patent None District Court, D. Delaware	External link to document

Executive summary

Last updated: July 13, 2026

Purdue Pharma LP litigation against Collegium Pharmaceutical Inc. in case 1:15-cv-00260 targets Collegium’s opioid product line and its related product design and/or regulatory posture under the Hatch-Waxman framework. The dispute is concentrated on patent enforceability and infringement theories tied to Purdue’s patent estate, with the practical commercial stake centered on preventing or delaying generic or alternative entrants from obtaining FDA approval and launching competing extended-release oxycodone offerings. The case posture and outcomes determine when exclusivity can be enforced through patent injunctions and when the market shifts via authorized generic and/or Paragraph IV design-arounds.

No case-caption details, asserted patent numbers, venue court name, procedural milestones, or docket outcomes were provided, so this response cannot produce a complete and accurate litigation summary (claims, patents, rulings, settlement terms, or injunction timing) for Purdue Pharma LP v. Collegium Pharmaceutical Inc. | 1:15-cv-00260.

If you want a litigation-grade analysis (asserted patents, claim construction, infringement/noninfringement holdings, validity rulings, settlement date and terms, and commercial impact), the case-specific docket content is required.